NAOGEN PHARMA will be present at the 10th JFMN РJourn̩es Francophones de M̩decine Nucl̩aire from 21st to 23rd of march in BIARRITZ.
Meet us at booth N° 18.1 (Lemer Pax – Naogen Pharma) in Centre de Congrès Bellevue.
January 29th, 2024, Naogen Pharma prepares the commercial launch of a radiopharmaceutical drug “Made in Nantes”.
At the end of 2023, Naogen Pharma SAS, a Young Innovative Company (JEI) based in Nantes, obtained Marketing Authorization (MA) from the French National Agency for the Safety of Medicines and Health Products (ANSM) for the drug it has developed.
Founded in 2016 by Jean-François Chatal, a pioneer in nuclear medicine, buds of the research and development work of GIP Arronax (radioisotope) and Lemer Pax (automatic injector), Naogen Pharma has been led by Sylvain Fanier since 2020. The company manufactures and is preparing to market its radiopharmaceutical drug for non-invasive functional imaging.
Backed by family offices (Sigma, Jamo, Auxitex, CMNP, Med-Innov, Altur, Le Doussal, Lafitte, Jacques), ICO Innov, a consortium of Grand Ouest banks (BPI, BPGO and CIC), the Pays de la Loire Region and the French State via a government grant, Naogen Pharma has benefited from over €10 million in financing, including €6.6 million in fundraising (equity) and €3.3 million in bank loans.
In 2023, Naogen Pharma had 15 employees under direct contracts, rising to 24 in 2024, to ensure GMP (Good Manufacturing Practice) production and commercial launch, thus demonstrating the
company’s determination to establish a long-term presence and contribute to the development of the industrial fabric, economic dynamism, strengthening of the healthcare ecosystem, European
leadership and international influence of the Pays de la Loire region in the radiopharmaceutical field.
This success of the radiopharmaceutical industry in the Pays de la Loire region is the fruit of many years of intense R&D efforts and investment in industrial production facilities, strongly supported by the French government and local authorities, notably through the funding of the “Quanticardi” (FUI) and “Go Radiopharma” (Plan de Relance) projects, and the “BioOuest Laennec” business incubator provided by Nantes University Hospital, through Nantes Métropole and Loire Océan Développement. In addition, it confirms the vocation of the Grand-Ouest Atlanpole Biotherapies healthcare cluster as a “project factory” to “product factory”, and the key role of the Atlanpole territorial HUB in supporting the growth of companies.
Contact
Sylvain Fanier
Président
s.fanier@naogen-pharma.com
Tel +336 07 59 01 67
Naogen Pharma SAS
Centre BioOuest Laennec
Rue du Moulin de la Rousselière
44800 Saint Herblain
www.naogen-pharma.com
October 2023 – Naogen Pharma selected to take part of the Innovative Healthcare International Acceleration Programme
Naogen Pharma is a winner of the Innovative Healthcare International Acceleration Award.
The Pays de la Loire Region and Atlanpole Biothérapies, in partnership with Business France, CCI Pays de la Loire, Altios and katalyse, will be working alongside us for 18 months to help us structure and refine our international development strategy.
July 2023 – Naogen Pharma presents at EANM- Vienna (Austria)
We will be present at EANM 2023 in Vienna.
See us at booth # 419 (Lemer Pax/Global Morpho Pharma).
JUNE 2023 – NAOGEN PHARMA PRESENTS AT SOFRA
Naogen Pharma will be at the national congress of the Société Française de Radiophamarcie SoFRa on the 8th and 9th of June at the Cité Universitaire in Paris.
It would be great to see you there.
https://sofra-radiopharmacie.org/evenements-sofra/article/12emes-rdv-de-la-sofra-8-et-9-juin-2023-sur-paris
APRIL 2023 –NAOGEN’S PARTICIPATION IN START WEST
On Thursday 6th April 2023, Naogen Pharma participated in the 23rd edition of Start West which took place at the CCI Nantes-St Nazaire.
Start West is an annual event dedicated to innovation and entrepreneurship in France.
Bringing together start-ups, investors, entrepreneurs and experts, this event encourages exchanges and collaborations.
As one of the 5 nominees in the health category, Naogen Pharma had the opportunity to present its development plan and vision of the future to an independent jury of experts.
To conclude this day rich in meetings, Naogen Pharma was named “Coup de Coeur” by Euronext.
March 2023 – Naogen Pharma presents at JFMN
We will be present at the 9èmes Journées Françaises de Médecine Nucléaire (JFMN)
www.cnp-mn.fr/sfmn-accueil/jfmn-2023-2
March 1st, 2023 in Nantes- Saint-Herblain, France, Naogen Pharma appoints Edwin Latouche as new Head of Manufacturing
Naogen Pharma appoints Edwin Latouche as new head of Manufacturing.
Edwin Latouche will oversee the manufacturing of our rubidium 82 generators at the French premises of Saint-Herblain. His role will be to lead the team and maintain production conditions.
Prior to joining the company, Edwin demonstrated his skills through various production optimisation projects in France and abroad on sterile or chemical distribution premises.
With a Pharm. D. and a master’s degree in industrial production management, he has completed his professional career with an interest in Lean Management. He will bring his vision and insight to the production at Naogen Pharma.
We wish him all the best in his new adventure.
December 1st, 2022 in Nantes – Saint-Herblain, France, Naogen Pharma appoints Stela Prapeau as Quality Assurance Manager
Stela Prapeau joins the Naogen Pharma team as Quality Assurance Manager.
Stela will be responsible for defining and coordinating the implementation of the quality assurance policy in terms of methods, organisation, processes and auditing, and will also be responsible for quality indicators.
She will lead the quality of all teams within Naogen Pharma by providing her expertise in order to ensure the safety of health products.
Stela will ensure compliance with regulatory standards and requirements.
Prior to joining the company, Stela worked as a Quality Assurance Engineer in biopharmaceutical companies, including manufacturers of active substances with international applications.
We are delighted to rely on Stela’s expertise and wish her every success in her new career.
July 18, 2022, in Nantes- Saint-Herblain, France, Naogen Pharma appoints Sahar Daoud as Quality Control Manager
Sahar Daoud joins Naogen Pharma as Quality Control Manager.
Sahar will organise all supply operations and ensure the control of raw materials and finished products within the Naogen Pharma laboratory. She will set up the control procedures and techniques and will ensure the documentary management.
Sahar has a master’s degree in analytical chemistry and previously worked at Novartis as a quality control engineer. She was responsible for performing routine analyses, transferring, and validating different methodologies and assisting in the qualification of laboratory equipment.
We are pleased to welcome Sahar Daoud and wish her every success in her new career.